BTL Files International Patent Infringement Lawsuit Against WonderFace Device

BTL Initiates Patent Infringement Lawsuit Against WonderFace

In a significant move on October 8, 2025, BTL Group, a leading provider of medical solutions worldwide, has launched an international patent infringement lawsuit against Lexter Microelectronic Engineering Systems S.L., the manufacturer of the WonderFace device. This legal action has been filed at the Unified Patent Court and is set to impact numerous jurisdictions.

The lawsuit highlights BTL's rights over its cutting-edge EMFACE® technology, which is known for revolutionizing facial tightening treatments. By combining selective muscle stimulation with radiofrequency heating, the EMFACE® technology has established a new category of facial treatment, allowing for customized and effective results without the need for invasive procedures. This innovative approach has led to a dramatic shift in how facial rejuvenation is approached in the medical and cosmetic fields.

According to Tomas Schwarz, CEO of the BTL Enterprise Group, the company is determined to protect its intellectual property vigorously. "We will aggressively defend our intellectual property to safeguard our customers’ investments. This lawsuit is the beginning of our extensive efforts against any third party that we believe infringes upon our innovations," Schwarz stated. This declaration underscores BTL's commitment to innovation and highlights the strategic importance of protecting technological advancements in a competitive market.

The lawsuit's implications are far-reaching, as a ruling in this case will affect operations across 18 jurisdictions, underlining the extensive reach of BTL's enforcement actions. The company is taking a firm stance against potential infringement that could compromise their innovative edge and market position.

Background on BTL and EMFACE Technology
Founded in 1993, BTL has positioned itself as a global leader in the medical device industry, delivering innovative solutions across various medical fields such as dermatology, plastic surgery, orthopedics, rehabilitation, and more. With a portfolio boasting over 200 patents and more than 600 engineers, BTL leverages technology and scientific research to enhance medical treatments.

The EMFACE® technology, at the center of the lawsuit, emphasizes the unique integration of muscle stimulation and radiofrequency, providing a non-invasive option for facial lifting and rejuvenation. This approach not only offers patients visible results but is also aligned with current trends in minimizing downtime and maximizing safety in medical procedures.

Moreover, BTL’s comprehensive product lineup includes notable innovations like EXION®, EMSCULPT NEO®, EXOMIND®, and EMSELLA®, each designed to push the boundaries of medical technology and improve patient outcomes. As BTL continues to innovate and expand its offerings, the protection of its intellectual property becomes paramount in ensuring ongoing success and leadership in the industry.

For those interested in learning more about the EMFACE technology and its applications, further details can be found on www.emface.com.

In conclusion, BTL's recent filing against WonderFace emphasizes the critical nature of patent protections in the rapidly evolving medical device landscape. As companies strive to innovate and differentiate themselves in their offerings, legal measures such as this lawsuit are essential in maintaining the integrity of their innovations and ensuring a fair competitive environment in the industry.